Dabur Pharma announces results for Fiscal 2006-07
Annual Sales at Rs. 322 crores, growth of 19% over 05-06. Profit after Tax up 36% to Rs. 25.2 crores
Q4 sales up 12.4 % to Rs 59.60 crores; profit before tax for the same period up by 396% to Rs 349.64 lakhs.
The Board of Dabur Pharma Limited (DPL) (NSE: DABURPHARM, BSE: 532545) met here today to consider the audited financial results of the company for the quarter & fiscal ended 31st March 2007.
The company’s sales grew by 19% during the year to end at Rs. 322 crores, up from Rs. 270 crores during the previous year. Profit (before tax) also increased by 34% from Rs. 22.32 crores to Rs. 29.91 crores during the same period.
During the quarter, the company posted a 12.4% increase in its turnover from Rs 53.01 crores to Rs 59.60 crores. Profit (before tax) increased from Rs 70.50 lacs to Rs 349.64 lakhs during the quarter.
Commenting on the growth, Dr. Anand Burman, Chairman Dabur Pharma Limited, said “FY 2006-07 was a milestone year for the company, a year of significant growth, research and innovation that led to the launch of an array of new products, including Nanoxel – the first indigenously developed nanotechnology based chemotherapy agent in the country”.
Speaking on the occasion, Mr. Ajay K. Vij, CEO, Dabur Pharma Limited said “We’re very excited about our ventures in some key markets like US & EU and have intensified our development efforts to bring molecules to these markets much faster than before. Also, through the acquisition of the Thai business and the divestment of our non-oncology portfolio to Alembic, the Company is poised for highly focused growth”.
Sourced From : Imprimis Life PR Pvt Ltd
Fresenius Kabi stock price
On , 0, Fresenius Kabi Oncology closed at Rs 132.45, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 161.40 and the 52-week low was Rs 93.10.
The latest book value of the company is Rs 42.55 per share. At current value, the price-to-book value of the company was 3.11.
Set email alert for
ADS BY GOOGLE
video of the day
See choppy mkt till earnings weak, be stock-specific